Zacks.com on MSN1d
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...
A Mathematician Who Makes the Best of Things
Alessio Figalli studies optimal transport, a field of math that ranges from the movements of clouds to the workings of ...
The Boston Globe14d
At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...
Investopedia14d
World Trade Organization (WTO): What It Is and What It Does
Robert Kelly is managing director of XTS Energy LLC, and has more than three decades of experience as a business executive. He is a professor of economics and has raised more than $4.5 billion in ...
Wall Street Journal15d
Vertex Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
USA Today15d
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The medication will be sold under the brand name Journavx for $15.50 per pill, according to Vertex Pharmaceuticals, the company that developed the new drug. The FDA's sign-off on the medication ...
MarketWatch15d
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment. It’s the first new class ...
Business Insider15d
Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to $550.00. Andrew Fein has given his Buy rating due ...
Morningstar15d
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
It's the first new class of pain treatment approved in more than 20 years, Vertex says. Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday's market open after the Food and Drug ...
MedCity News15d
Vertex Pharma’s Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds
A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative ...
WVTM 1316d
FDA approves new pain drug Journavx as opioid alternative
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to ...